Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells
SARS-CoV viruses have been shown to downregulate cellular events that control antiviral defenses. They adopt several strategies to silence p53, key molecule for cell homeostasis and immune control, indicating that p53 has a central role in controlling their proliferation in the host. Specific action...
Main Authors: | Giada Lodi, Valentina Gentili, Fabio Casciano, Arianna Romani, Giorgio Zauli, Paola Secchiero, Enrico Zauli, Carolina Simioni, Silvia Beltrami, Mercedes Fernandez, Roberta Rizzo, Rebecca Voltan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1018761/full |
Similar Items
-
MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma
by: Arianna Romani, et al.
Published: (2022-10-01) -
Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
by: Erika Rimondi, et al.
Published: (2021-07-01) -
Microfluidic Fabricated Liposomes for Nutlin-3a Ocular Delivery as Potential Candidate for Proliferative Vitreoretinal Diseases Treatment
by: Esposito E, et al.
Published: (2024-04-01) -
Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma
by: Joon Hee Kang, et al.
Published: (2020-06-01) -
Methoxyphenyl Imidazolines as Potential Activators of p53
by: Daniil R. Bazanov, et al.
Published: (2022-11-01)